Indo Borax Board Approves Shashikant Bharuka as CFO Effective March 2026
Indo Borax & Chemicals has appointed Shashikant Bharuka as Chief Financial Officer effective March 06, 2026, following board approval on February 25, 2026. The qualified CA and CS brings over 24 years of post-qualification experience from prominent pharmaceutical companies including Lupin Limited, Unichem Laboratories, Ajanta Pharma, and IPCA Labs, with expertise spanning financial reporting, audit management, and international consolidation across USA, South Africa, and Brazil subsidiaries.

*this image is generated using AI for illustrative purposes only.
Indo Borax & Chemicals has officially announced the appointment of Shashikant Bharuka as its Chief Financial Officer through a board resolution passed on February 25, 2026. The appointment, which takes effect from March 06, 2026, was approved based on recommendations from both the Audit Committee and Nomination and Remuneration Committee.
Board Meeting Outcome
The company's Board of Directors convened on February 25, 2026, from 11:44 a.m. to 12:30 p.m. to deliberate on key organizational matters. The primary agenda included the strategic appointment of Bharuka as Chief Financial Officer and Key Managerial Personnel, along with approval of a draft postal ballot notice for seeking shareholders' approval on proposed resolutions.
| Meeting Details: | Information |
|---|---|
| Date: | February 25, 2026 |
| Duration: | 11:44 a.m. to 12:30 p.m. |
| Key Decisions: | CFO Appointment & Postal Ballot Notice |
| Effective Date: | March 06, 2026 |
Professional Qualifications and Experience
Bharuka brings substantial credentials to his new role, holding dual qualifications as both a Chartered Accountant (CA) and Company Secretary (CS). His professional journey spans over 24 years of post-qualification experience in finance and accounts management, primarily within public listed companies.
Comprehensive Skill Set
His expertise encompasses multiple critical areas including accounting and audit management, financial reporting, accounts finalization, tax compliances, cost savings initiatives, payroll management, control design, and system implementation. Additionally, he has demonstrated proficiency in process improvement, automation initiatives, business support, and stakeholder management.
Career Trajectory
Bharuka's professional background reflects extensive experience across prominent pharmaceutical companies. His most recent tenure was with Lupin Limited, where he focused on corporate accounts, payable and receivable management, and auditor relations. He has resigned and is currently serving his notice period at Lupin.
| Career Timeline: | Company | Duration | Key Responsibilities |
|---|---|---|---|
| Current: | Lupin Limited | Latest Role | Corporate Accounts, Audit Management |
| Previous: | Unichem Laboratories Limited | 9 Years | Consolidation, Financial Reporting, Tax Compliance |
| Earlier: | Ajanta Pharma | 2+ Years | Financial Operations |
| Initial: | IPCA Laboratories Limited | 2 Years | Finance and Accounts |
International Experience
During his tenure at Unichem Laboratories Limited, Bharuka managed the consolidation of foreign subsidiaries across multiple international markets including the USA, South Africa, and Brazil. This global exposure adds valuable international financial management perspective to his role at Indo Borax & Chemicals.
Regulatory Compliance
The appointment follows proper corporate governance protocols, with the company filing the necessary disclosures under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The board also approved a draft postal ballot notice for seeking shareholders' approval on proposed resolutions, which will be dispatched to shareholders in due course. The detailed disclosure was submitted to both BSE Limited (Stock Code: 524342) and National Stock Exchange of India Ltd (Stock Code: INDOBORAX).
Historical Stock Returns for Indo Borax & Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.37% | -0.56% | +0.08% | -5.74% | +53.84% | +64.98% |


































